CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 43 enrolled
Drug / intervention
Bravelle and Menopur +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01669291
NCT01669291N/ACompleted
CompareCT.gov

Effect of GnRH Antagonist Protocol vs Agonist Long Protocol During Controlled Hyperstimulation (COH)for Assisted Reproduction on IVF Outcome, Peak Estradiol Level, and Duration of Stimulation.

Main Line Fertility Center·interventional·Posted Aug 21, 2012·Updated Jun 4, 2014

In Brief

A clinical study evaluating Bravelle and Menopur, Agonist, and 1 other intervention for Fertility. Completed, enrolled 43 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if utilizing GnRH antagonists versus agonist long protocol during controlled ovarian stimulation (COH) with human-derived gonadotropins for assisted reproduction affects IVF outcome, peak estradiol level, and duration of stimulation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFertility
CountriesUnited States
CollaboratorsFerring Pharmaceuticals

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 21, 2012
Enrollment StartJul 1, 2012
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.9 years ago

Interventions

Bravelle and Menopurdrug

Bravelle and Menopur are used for controlled ovarian stimulation (COH)

Agonistdrug

Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.

Antagonistdrug

Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.